Illumina, Inc. (ILMN)

Illumina's stock has been impacted by stronger-than-expected earnings for the first quarter of 2026, with revenue and EPS surpassing analyst forecasts, leading to a stock rise. The company posted a non-GAAP EPS of $1.15 and revenue of $1.09 billion, driven by strong demand for sequencing consumables and instruments, particularly in clinical applications, and the robust uptake of the NovaSeq X platform. Management raised its full-year 2026 revenue and adjusted EPS guidance, approved a new $1.5 billion share repurchase program, and completed the acquisition of SomaLogic.

Illumina experiences demand seasonality for its products and services, with a seasonal increase in ordering activity and backlog build for consumables, particularly in the first quarter.

Illumina, Inc. is a global biotechnology company specializing in integrated systems for genetic variation and biological function analysis, serving academic, government, pharmaceutical, biotechnology, and clinical institutions worldwide. Its major products include sequencing systems, consumables, microarray systems, software and informatics solutions, and genomic services.

Illumina has a significant global presence, serving over 155 countries across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region. Its worldwide headquarters are in San Diego, California, with additional commercial offices in the USA and international locations including the UK, Japan, Australia, New Zealand, China, Dubai, France, Germany, India, Korea, Latin America, and the Netherlands.

Illumina's brand reputation has been influenced by its strategic adjustments and ongoing innovation, including the divestiture of GRAIL following regulatory challenges. Despite these challenges, Illumina continues to be recognized as a global leader in DNA sequencing and array-based technologies. The launch of BioInsight aims to strengthen its leadership in supporting pharmaceutical companies in drug target discovery and development.

Illumina's ownership is predominantly institutional, with institutional investors holding over 92% of outstanding shares. Major institutional owners include Capital World Investors, The Vanguard Group, BlackRock Institutional Trust Company, and State Street Investment Management. Insider ownership remains under 1%, with recent insider trading activity showing officers selling shares and some directors buying shares.